Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice

[1]  B. de Strooper,et al.  Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice , 2012, Molecular Neurodegeneration.

[2]  A. Sabirsh,et al.  First and Second Generation γ-Secretase Modulators (GSMs) Modulate Amyloid-β (Aβ) Peptide Production through Different Mechanisms , 2012, The Journal of Biological Chemistry.

[3]  Y. Shitaka,et al.  Differential Effects between γ-Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice , 2012, The Journal of Neuroscience.

[4]  F. Checler,et al.  The physiology of the β‐amyloid precursor protein intracellular domain AICD , 2012, Journal of neurochemistry.

[5]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[6]  A. Lleó,et al.  γ-secretase substrates and their implications for drug development in Alzheimer's disease. , 2011, Current topics in medicinal chemistry.

[7]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[8]  N. Ramsden,et al.  Chronic treatment with a novel γ‐secretase modulator, JNJ‐40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease , 2011, British journal of pharmacology.

[9]  J. Richardson,et al.  Dynamics of Aβ42 Reduction in Plasma, CSF and Brain of Rats Treated with the γ-Secretase Modulator, GSM-10h , 2011, Neurodegenerative Diseases.

[10]  M. Ferretti,et al.  Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? , 2011, Current Alzheimer research.

[11]  G. Logroscino,et al.  Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? , 2011, Expert opinion on investigational drugs.

[12]  Daniel Oehlrich,et al.  γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. , 2011, Journal of medicinal chemistry.

[13]  R. Motter,et al.  Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease , 2010, Alzheimer's Research & Therapy.

[14]  Xulun Zhang,et al.  Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease , 2010, Neuron.

[15]  T. V. Van Dooren,et al.  Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model , 2010, International journal of Alzheimer's disease.

[16]  Robert C Green,et al.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.

[17]  Y. Oda,et al.  Synaptic activity prompts γ-secretase–mediated cleavage of EphA4 and dendritic spine formation , 2009, The Journal of cell biology.

[18]  E. Koo,et al.  Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.

[19]  Ottavio Arancio,et al.  A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment , 2008, Neurobiology of Disease.

[20]  S. Hendrix,et al.  Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial , 2008, The Lancet Neurology.

[21]  B. de Strooper,et al.  1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel γ-Secretase Modulator, Reduces Brain β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity , 2007, Journal of Pharmacology and Experimental Therapeutics.

[22]  Michael S. Wolfe,et al.  Presenilin: Running with Scissors in the Membrane , 2007, Cell.

[23]  Henrik Zetterberg,et al.  Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. , 2007, Journal of proteome research.

[24]  Patrick L. McGeer,et al.  NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies , 2007, Neurobiology of Aging.

[25]  P. Mehta,et al.  Humoral immune responses to peptides derived from the β-amyloid peptide C-terminal sequence , 2007, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[26]  B. Strooper,et al.  Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms , 2006, Journal of neurochemistry.

[27]  B. Hyman,et al.  APP substitutions V715F and L720P alter PS1 conformation and differentially affect Aβ and AICD generation , 2005, Journal of neurochemistry.

[28]  T. Comery,et al.  Acute γ-Secretase Inhibition Improves Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[29]  S. Hébert,et al.  Differential contribution of the three Aph1 genes to γ-secretase activity in vivo , 2005 .

[30]  A. Nadin,et al.  Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target γ-Secretase at a Novel Site , 2004, Journal of Biological Chemistry.

[31]  Jay S. Fine,et al.  Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation* , 2004, Journal of Biological Chemistry.

[32]  S. Weggen,et al.  The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κB Kinase, and NFκB, Do Not Reduce Amyloid β42 Production* , 2003, Journal of Biological Chemistry.

[33]  S. Weggen,et al.  Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity* , 2003, Journal of Biological Chemistry.

[34]  M. Citron,et al.  Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease , 2003, The Journal of Neuroscience.

[35]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[36]  D. Beher,et al.  Generation of C‐terminally truncated amyloid‐β peptides is dependent on γ‐secretase activity , 2002 .

[37]  George A. Carlson,et al.  The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[38]  James P. O'Callaghan,et al.  Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse , 2002, Experimental Neurology.

[39]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[40]  Raphael Kopan,et al.  Murine Notch Homologs (N1–4) Undergo Presenilin-dependent Proteolysis* , 2001, The Journal of Biological Chemistry.

[41]  M. Staufenbiel,et al.  Comparative Analysis of Amyloid-β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains* , 2001, The Journal of Biological Chemistry.

[42]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[43]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[44]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[45]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[46]  I. Lieberburg,et al.  Cellular mechanisms of beta-amyloid production and secretion. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[47]  William J. Ray,et al.  A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain , 1999, Nature.

[48]  D. Borchelt,et al.  Effects of PS1 Deficiency on Membrane Protein Trafficking in Neurons , 1998, Neuron.

[49]  Hugo Vanderstichele,et al.  Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.

[50]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[51]  T. Iwatsubo,et al.  Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain , 1996, Neuroscience Letters.

[52]  T. Iwatsubo,et al.  Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.

[53]  L. Hunihan,et al.  Altered cleavage and secretion of a recombinant β–APP bearing the Swedish familial Alzheimer's disease mutation , 1994, Nature Genetics.

[54]  G. Brewer,et al.  Optimized survival of hippocampal neurons in B27‐supplemented neurobasal™, a new serum‐free medium combination , 1993, Journal of neuroscience research.

[55]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Murphy,et al.  Alzheimer’s Disease and the β -Amyloid Peptide , 2010 .

[57]  M. Murphy,et al.  Alzheimer's disease and the amyloid-beta peptide. , 2010, Journal of Alzheimer's disease : JAD.

[58]  S. Hébert,et al.  Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[60]  Greg D. Gale,et al.  Hippocampus and contextual fear conditioning: Recent controversies and advances , 2001, Hippocampus.

[61]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .